Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease

Table 4 Ulcerative colitis study characteristics

Author and study center	Study design	Total patients	Study endpoints	Concomitant medication	Case (%)	Control (%)	P value	IFX dosing	Last dose of IFX prior to surgery < 12 wk
Selvasekar[25], 2007, Mayo Clinic, Rochester	Case-control	301 patients, 47 cases, 254 controls	Post-operative pouch specific and infectious complications	5-ASA	100	60	< 0.0001	Scheduled (majority)	49% (< 8 wk)
				6MP/AZA	91	44	< 0.0001
				Steroids	47	77	< 0.001
				Steroids + AZA	70	21	< 0.001
Schluender[26], 2007, Cedars-Sinai LA	Case-control	151 patients, 17 cases, 134 controls	30 d post-operative surgical and medical complications	5-ASA	-	-	-	2 infusions (median)	Majority (8 wk median)
				6MP/AZA	94	44	0.03
				Steroids	100	100	1
Mor[27], 2008, Cleveland Clinic	Case-control	92 patients, 46 cases, 46 controls	Early (30 d) and late post-operative complications	5-ASA	-	-	-	3 infusions (median)	Majority (13.5 wk median)
				6MP/AZA	39	28	0.27
				Steroids	2 ( ranked dose score)
						2.24	0.42
Ferrante[28], 2009, Belgium	Case-control	141 patients, 22 cases, 119 controls	Early (30 d) post-operative complications	5-ASA				Scheduled 2.5 Infusions (median)	Majority (3.9 wk median)
				6MP/AZA	59	55	0.7
				Steroids (high dose)	9	25	0.163
Kunitake[29], 2008, Massachusetts General Hospital, Boston (combined study)	Case-control	413 total, 101 cases, 312 control	Post-operative complications	5-ASA	-	-	-	-	100%
				6MP/AZA	37	26	0.04
				Steroids	75.30	77	0.79
				Antibiotics	-	-	-

IFX: Infliximab; 5-ASA: 5-aminosalicylic acid; AZA: Azathioprine; 6MP: 6-mercaptopurine.